Spinal Cord Injury
Conditions
Keywords
neurophysiological parameters improvement, spinal cord injury, biology therapy
Brief summary
The purpose of this study is to confirm the security, and detect the effect of the local administration in damaged nervous tissue, of autologous bone marrow stromal cells.
Detailed description
It is a clinical trial phase I, single center, non-randomized, uncontrolled, open prospective follow-up of a cohort of patients with chronic spinal cord injury (SCI) who were treated with autologous stromal cells of the bone marrow administrated locally (subarachnoid and intramedullar) by intrathecal microinjection and three months later, by lumbar subarachnoid administration. The minimum follow-up duration for each patient is 12 months after the first administration, or until death, if it occurs it before.
Interventions
BIOLOGICALMesenchymal stromal cell therapy
Stem cells administration locally
Sponsors
Puerta de Hierro University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Male or female with ages between 18 years and 60 years with of age or older functional sequelae chronically established by traumatic injury of the spinal cord (spinal segments between the vertebral bodies C6 and L1) and considered irreversible (not respond to any other treatment). In this study, the lesion is considered chronically established, when there are no signs of functional recovery after a minimum follow-up period of 6 months after the spinal cord injury. The upper age limit is justified by the low potential of in vitro expansion of bone marrow stromal cells over 60 years. * Complete paraplegia, with loss of motor and sensory function below the lesion (grade A in the American Spinal Injury Association Impairment (ASIA) Scale . * Spinal injury MRI morphologically visible, and without images that suggest spinal cord transection, with separation of the both ends of the spinal cord. * Tracking evolutionary possibility after treatment protocol and to comply physiotherapy maintained throughout the follow up period. * Written informed Consent according to good clinical practice (GCP) and local regulations, obtained before any study procedure. * Hematological parameters and creatinine, serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) in normal range according to laboratory standards, are accepted, however, small non-significant deviations according to the investigator.
Exclusion criteria
* Pregnancy and lactation * Systemic disease represents an added risk to treatment * Patients with questions about their possible cooperation in rehabilitation-physiotherapy treatments later, or negative report psychological assessment prior. * Neuroimaging data showing spinal cord section with separation of the terminal portion of the spinal cord * Current neoplastic disease diagnosed or treated in the previous five years * Patients treated with hematopoietic growth factors or requiring stable anticoagulation * Added neurodegenerative disease * History of substance abuse, psychiatric illness or allergy to protein products used in the process of cell expansion * HIV positive serology and syphilis * Hepatitis B or Hepatitis C active According to the investigator's opinion if there are findings on physical examination, abnormal clinical test results or other medica relevant entries, social or psychosocial factors which might influence negatively the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety-Number of Adverse Events | Up to 12 months | Clinical evaluation of possible adverse effects is performed daily at the first week after the first administration of stem cells and weekly until the 6 months follow-up visit and then at month 9 and 12. . * During the first stem cells administration (during surgery): Changes in vital signs (ECG, Blood Pressure (BP), Heart Rate (HR) were evaluated * During the second stem cells administration: Changes in vital signs (BP, HR), headache and meningeal irritation were evaluated * During the first weeks, after the first and the second administrations, the possibility of meningeal irritation, headache and infectious complications were considerate. MedDRA stardards are followed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy-Sensitivity Recovery Using ASIA Scale | sensitivity before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period) | Sensitivity recovery was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation. ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 12 patients were obtained at all the time points and statistically analyzed. |
| Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section) | Changes in the level of Chronic pain before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period) | Changes in the level of chronic pain, measured by the pain section of the IANR-SCIFRS (Spinal cord injury functional rating scale (SCI-FRS) of the international association of neuroestoratology (IANR). The minimum posible score is 0, and the máximum posible score is 48, being a score of 48 a normal functioning across all categories, and 0 a severe degree of functional hándicap (significant impact of daily life). Pain is classified as no pain; mild pain, ordinary pain killer, effective;severe pain, narcotics required; extreme pain, uncontrolled. |
| Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials) | Changes in the level neurophysiological parameters improvement (baseline visit) and 6, 12 months after surgery (follow-up period) | Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as number of patients WITH SSEPs, each patient through underwent neurophysiological studies before treatment, as well as six and 12 months after surgery, paying attention mainly to the presence or abscence of somatosensory evoked potentials (SSEPs), the presence or absence of motor evoked potentials (MEPs) elicited by magnetic stimulation over the scalp, and to electromyographic (EMG) recording of motor unit potentials in infralesional muscles. Previous to cell therapy in any of the patients SSEPs were recorded. |
| Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity | Urodynamic studies before surgery and 12 months after surgery (follow-up period) | Urodynamic studies in terms of voluntary micturition in flowmetry or in pressure/flow test, increase in bladder compliance. detrusor pressure (decrease on detrusor pressure is considered a clinical improvement). The neurogenic bladder is one of the biggest problems associated with SCI (spinal cord injury), with important personal and social implications. |
| Efficacy-modification of Magnetic Resonance Imaging (MRI) | changes in the spinal cord morphology on neuroimaging studies before surgery and 12 months after surgery (follow-up period) | Number of patients with a decrease in volume and hyperintensity of intramedullary lesions. In general, in the areas of SCI, variable degree of spinal cord atrophy and hiperintense images are observed. These images corresponds to cysts, gliosis and myelomalacia. After cell administration a reduction of supposed cyst and a decrease or disappearance of hyperintense lesions suggest a patient improvement. |
Countries
Spain
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Mesenchymal Stromal Cell Therapy Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x10\^6 followed by subarachnoid administration of 30x10\^6 MSCs,3 months later
Mesenchymal stromal cell therapy | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | Mesenchymal Stromal Cell Therapy |
|---|---|
| Age, Continuous | 40.5 years STANDARD_DEVIATION 8.75 |
| Region of Enrollment Spain | 12 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 12 / 12 |
| serious Total, serious adverse events | 0 / 12 |
Outcome results
Primary
Safety-Number of Adverse Events
Clinical evaluation of possible adverse effects is performed daily at the first week after the first administration of stem cells and weekly until the 6 months follow-up visit and then at month 9 and 12. . * During the first stem cells administration (during surgery): Changes in vital signs (ECG, Blood Pressure (BP), Heart Rate (HR) were evaluated * During the second stem cells administration: Changes in vital signs (BP, HR), headache and meningeal irritation were evaluated * During the first weeks, after the first and the second administrations, the possibility of meningeal irritation, headache and infectious complications were considerate. MedDRA stardards are followed
Time frame: Up to 12 months
Population: Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Mesenchymal Stromal Cell Therapy | Safety-Number of Adverse Events | 69 Adverse events |
Secondary
Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)
Changes in the level of chronic pain, measured by the pain section of the IANR-SCIFRS (Spinal cord injury functional rating scale (SCI-FRS) of the international association of neuroestoratology (IANR). The minimum posible score is 0, and the máximum posible score is 48, being a score of 48 a normal functioning across all categories, and 0 a severe degree of functional hándicap (significant impact of daily life). Pain is classified as no pain; mild pain, ordinary pain killer, effective;severe pain, narcotics required; extreme pain, uncontrolled.
Time frame: Changes in the level of Chronic pain before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mesenchymal Stromal Cell Therapy | Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section) | Before Surgery | 2.00 units on a scale | Standard Deviation 0.95 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section) | 3 months after surgery | 2.25 units on a scale | Standard Deviation 0.97 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section) | 6 months after surgery | 2.42 units on a scale | Standard Deviation 0.9 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section) | 9 months after surgery | 2.42 units on a scale | Standard Deviation 0.9 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section) | 12 months after surgery | 2.58 units on a scale | Standard Deviation 0.79 |
Secondary
Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)
Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as number of patients WITH SSEPs, each patient through underwent neurophysiological studies before treatment, as well as six and 12 months after surgery, paying attention mainly to the presence or abscence of somatosensory evoked potentials (SSEPs), the presence or absence of motor evoked potentials (MEPs) elicited by magnetic stimulation over the scalp, and to electromyographic (EMG) recording of motor unit potentials in infralesional muscles. Previous to cell therapy in any of the patients SSEPs were recorded.
Time frame: Changes in the level neurophysiological parameters improvement (baseline visit) and 6, 12 months after surgery (follow-up period)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Mesenchymal Stromal Cell Therapy | Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials) | Before Surgery | 0 number of patients with SSEPs |
| Mesenchymal Stromal Cell Therapy | Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials) | 6 months after surgery | 5 number of patients with SSEPs |
| Mesenchymal Stromal Cell Therapy | Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials) | 12 months after surgery | 7 number of patients with SSEPs |
Secondary
Efficacy-modification of Magnetic Resonance Imaging (MRI)
Number of patients with a decrease in volume and hyperintensity of intramedullary lesions. In general, in the areas of SCI, variable degree of spinal cord atrophy and hiperintense images are observed. These images corresponds to cysts, gliosis and myelomalacia. After cell administration a reduction of supposed cyst and a decrease or disappearance of hyperintense lesions suggest a patient improvement.
Time frame: changes in the spinal cord morphology on neuroimaging studies before surgery and 12 months after surgery (follow-up period)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Mesenchymal Stromal Cell Therapy | Efficacy-modification of Magnetic Resonance Imaging (MRI) | Before Surgery | 0 Patients |
| Mesenchymal Stromal Cell Therapy | Efficacy-modification of Magnetic Resonance Imaging (MRI) | 12 months after surgery | 7 Patients |
Secondary
Efficacy-Sensitivity Recovery Using ASIA Scale
Sensitivity recovery was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation. ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 12 patients were obtained at all the time points and statistically analyzed.
Time frame: sensitivity before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mesenchymal Stromal Cell Therapy | Efficacy-Sensitivity Recovery Using ASIA Scale | Before Surgery | 165.92 units on a scale | Standard Deviation 22.83 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Sensitivity Recovery Using ASIA Scale | 3 months after surgery | 181.25 units on a scale | Standard Deviation 22.9 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Sensitivity Recovery Using ASIA Scale | 6 months after surgery | 189.83 units on a scale | Standard Deviation 27.83 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Sensitivity Recovery Using ASIA Scale | 9 months after surgery | 200.75 units on a scale | Standard Deviation 34.4 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Sensitivity Recovery Using ASIA Scale | 12 months after surgery | 213.25 units on a scale | Standard Deviation 37.19 |
Secondary
Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity
Urodynamic studies in terms of voluntary micturition in flowmetry or in pressure/flow test, increase in bladder compliance. detrusor pressure (decrease on detrusor pressure is considered a clinical improvement). The neurogenic bladder is one of the biggest problems associated with SCI (spinal cord injury), with important personal and social implications.
Time frame: Urodynamic studies before surgery and 12 months after surgery (follow-up period)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mesenchymal Stromal Cell Therapy | Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity | Before Surgery | 77.50 cm/H2O | Standard Deviation 34.61 |
| Mesenchymal Stromal Cell Therapy | Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity | 12 months after surgery | 54.58 cm/H2O | Standard Deviation 22.88 |